Industry & Policy News

[University of Illinois (UI) Health] A new therapy for brittle type 1 diabetes, the only treatment currently approved by the US FDA, is available exclusively at UI Health in Chicago.

[Moffitt Cancer Center] Marisol Gallagher, with Drs. Robert Wenham and Monica Avila, received a second round of CAR T-cell therapy 18 months after her first round. Her care team hopes the second infusion will cure her ovarian cancer once and for all.

[UBC Faculty of Medicine] Twenty-eight projects led by Faculty of Medicine researchers, including Dr. Liam Brunham, have received new funding from Michael Smith Health Research BC through the 2024 Convening & Collaborating and Reach programs. Dr. Brunham will be studying genetic lipid disorders and premature atherosclerotic cardiovascular disease.

[Medera, Inc,] Medera, Inc. and The Cardiovascular Disease National Collaborative Enterprise of Singapore are pleased to announce the initiation of Asia’s first cardiac gene therapy clinical trial for heart failure in Singapore.

[Cytokinetics, Inc.] Cytokinetics, Inc.announced that the US FDA has accepted the company’s New Drug Application for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy.

[Fort Worth Report] Barricade Therapeutics, Corp. has received a $14,005,035 grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will support the Phase I clinical development of Barricade’s innovative therapeutic candidate BT-1501 for APC mut advanced colorectal cancer patients.